Joseph M Caster1, Aaron D Falchook1, Laura H Hendrix2, Ronald C Chen3. 1. Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 2. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 3. Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Electronic address: Ronald_chen@med.unc.edu.
Abstract
PURPOSE: Radiation oncologists rely on available clinical information (biopsy Gleason score and prostate-specific antigen [PSA]) to determine the optimal treatment regimen for each prostate cancer patient. Existing published nomograms correlating clinical to pathologic extent of disease were based on patients treated in the 1980s and 1990s at select academic institutions. We used the Surveillance, Epidemiology, and End Results (SEER) database to examine pathologic outcomes (Gleason score and cancer stage) in early prostate cancer patients based on biopsy Gleason score and PSA concentration. METHODS AND MATERIALS: This analysis included 25,858 patients whose cancer was diagnosed between 2010 and 2011, with biopsy Gleason scores of 6 to 7 and clinical stage T1 to T2 disease, who underwent radical prostatectomy. In subgroups based on biopsy Gleason score and PSA level, we report the proportion of patients with pathologically advanced disease (positive surgical margin or pT3-T4 disease) or whose Gleason score was upgraded. Logistic regression was used to examine factors associated with pathologic outcomes. RESULTS: For patients with biopsy Gleason score 6 cancers, 84% of those with PSA <10 ng/mL had surgical T2 disease with negative margins; this decreased to 61% in patients with PSA of 20 to 29.9 ng/mL. Gleason score upgrading was seen in 43% (PSA: <10 ng/mL) to 61% (PSA: 20-29.9 ng/mL) of biopsy Gleason 6 patients. Patients with biopsy Gleason 7 cancers had a one-third (Gleason 3 + 4; PSA: <10 ng/mL) to two-thirds (Gleason 4 + 3; PSA: 20-29.9 ng/mL) probability of having pathologically advanced disease. Gleason score upgrading was seen in 11% to 19% of patients with biopsy Gleason 4 + 3 cancers. Multivariable analysis showed that higher PSA and older age were associated with Gleason score upgrading and pathologically advanced disease. CONCLUSIONS: This is the first population-based study to examine pathologic extent of disease and pathologic Gleason score upgrading based on clinically available information in modern patients. These data inform the selection of radiation therapy strategies and an understanding of whether prostatectomy alone is likely to be curative for patients with early prostate cancers.
PURPOSE: Radiation oncologists rely on available clinical information (biopsy Gleason score and prostate-specific antigen [PSA]) to determine the optimal treatment regimen for each prostate cancerpatient. Existing published nomograms correlating clinical to pathologic extent of disease were based on patients treated in the 1980s and 1990s at select academic institutions. We used the Surveillance, Epidemiology, and End Results (SEER) database to examine pathologic outcomes (Gleason score and cancer stage) in early prostate cancerpatients based on biopsy Gleason score and PSA concentration. METHODS AND MATERIALS: This analysis included 25,858 patients whose cancer was diagnosed between 2010 and 2011, with biopsy Gleason scores of 6 to 7 and clinical stage T1 to T2 disease, who underwent radical prostatectomy. In subgroups based on biopsy Gleason score and PSA level, we report the proportion of patients with pathologically advanced disease (positive surgical margin or pT3-T4 disease) or whose Gleason score was upgraded. Logistic regression was used to examine factors associated with pathologic outcomes. RESULTS: For patients with biopsy Gleason score 6 cancers, 84% of those with PSA <10 ng/mL had surgical T2 disease with negative margins; this decreased to 61% in patients with PSA of 20 to 29.9 ng/mL. Gleason score upgrading was seen in 43% (PSA: <10 ng/mL) to 61% (PSA: 20-29.9 ng/mL) of biopsy Gleason 6 patients. Patients with biopsy Gleason 7 cancers had a one-third (Gleason 3 + 4; PSA: <10 ng/mL) to two-thirds (Gleason 4 + 3; PSA: 20-29.9 ng/mL) probability of having pathologically advanced disease. Gleason score upgrading was seen in 11% to 19% of patients with biopsy Gleason 4 + 3 cancers. Multivariable analysis showed that higher PSA and older age were associated with Gleason score upgrading and pathologically advanced disease. CONCLUSIONS: This is the first population-based study to examine pathologic extent of disease and pathologic Gleason score upgrading based on clinically available information in modern patients. These data inform the selection of radiation therapy strategies and an understanding of whether prostatectomy alone is likely to be curative for patients with early prostate cancers.
Authors: David T Miyamoto; Richard J Lee; Mark Kalinich; Joseph A LiCausi; Yu Zheng; Tianqi Chen; John D Milner; Erin Emmons; Uyen Ho; Katherine Broderick; Erin Silva; Sarah Javaid; Tanya Todorova Kwan; Xin Hong; Douglas M Dahl; Francis J McGovern; Jason A Efstathiou; Matthew R Smith; Lecia V Sequist; Ravi Kapur; Chin-Lee Wu; Shannon L Stott; David T Ting; Anita Giobbie-Hurder; Mehmet Toner; Shyamala Maheswaran; Daniel A Haber Journal: Cancer Discov Date: 2018-01-04 Impact factor: 39.397
Authors: Morgan L Zenner; Yves B Helou; Ryan J Deaton; Maria Sverdlov; Heng Wang; Andre Kajdacsy-Balla; Virgilia Macias; Cindy Voisine; Marcus Murray; Sarki A Abdulkadir; Adam B Murphy; Larisa Nonn Journal: Prostate Date: 2021-12-02 Impact factor: 4.104
Authors: Kathryn L Penney; Svitlana Tyekucheva; Jacob Rosenthal; Habiba El Fandy; Ryan Carelli; Stephanie Borgstein; Giorgia Zadra; Giuseppe Nicolò Fanelli; Lavinia Stefanizzi; Francesca Giunchi; Mark Pomerantz; Samuel Peisch; Hannah Coulson; Rosina Lis; Adam S Kibel; Michelangelo Fiorentino; Renato Umeton; Massimo Loda Journal: Mol Cancer Res Date: 2020-11-09 Impact factor: 5.852
Authors: Sue M Evans; Varuni Patabendi Bandarage; Caroline Kronborg; Arul Earnest; Jeremy Millar; David Clouston Journal: Prostate Int Date: 2016-08-03
Authors: Glen Denmer R Santok; Ali Abdel Raheem; Lawrence Hc Kim; Kidon Chang; Trenton Gh Lum; Byung Ha Chung; Young Deuk Choi; Koon Ho Rha Journal: Investig Clin Urol Date: 2017-02-15